文献速递中毒与环境急症重症综合管理与镇静镇痛

真实世界苯巴比妥使用、治疗升级与重症酒精戒断综合征患者的临床结局:多中心倾向匹配队列研究

Real-World Phenobarbital Use, Treatment Escalation, and Clinical Outcomes in Critically Ill Patients With Alcohol Withdrawal Syndrome: A Multicenter Propensity-Matched Cohort Study.
PubMed 文献 · Crit Care Explor · 2026-08-17
一句话结论在ICU酒精戒断综合征患者中,苯巴比妥使用反映治疗升级,校正后不显著改变出院时间,误吸更少。

这项多中心回顾性队列研究纳入CIWA-Ar≥10的成人酒精戒断综合征ICU患者,比较苯巴比妥为基础与非苯巴比妥方案。1216例中345例(28.4%)使用苯巴比妥,使用组基线CIWA-Ar、APACHE III及入ICU前苯二氮䓬暴露更高。校正后苯巴比妥与出院时间无显著关联(医院DRR 0.91,95%CI 0.74-1.12;ICU DRR 0.77,95%CI 0.59-1.01),低血压和插管相似,误吸更少。

要点

  • 苯巴比妥使用组基线CIWA-Ar、APACHE III和入ICU前苯二氮䓬暴露更高,提示其使用反映更严重或难治性戒断及治疗升级。
  • 校正后苯巴比妥与医院出院时间无显著关联(DRR 0.91;95%CI 0.74-1.12;p=0.370)。
  • 校正后苯巴比妥与ICU出院时间无显著关联(DRR 0.77;95%CI 0.59-1.01;p=0.057)。
  • 低血压和新插管在两组间相似,误吸在苯巴比妥组更少。
  • 研究为回顾性设计,苯巴比妥的最佳时机、剂量和患者选择尚待前瞻性研究确定。

适用人群与场景

  • 成人ICU酒精戒断综合征患者,定义为CIWA-Ar评分≥10,且接受苯巴比妥为基础或非苯巴比妥为基础方案。
  • 排除术后ICU入住患者。
  • 研究场景为大型学术健康系统内多个ICU,时间范围2017年6月30日至2024年7月1日。

诊断标准与关键阈值

  • 酒精戒断综合征定义:临床酒精戒断评估修订版(CIWA-Ar)评分≥10。

处置流程与药物剂量

  • 原文未提及具体苯巴比妥剂量、给药途径、频次或疗程。
  • 原文未提及非苯巴比妥方案的具体药物、剂量或方案细节。

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 研究类型:多中心回顾性队列研究,采用多重插补和倾向评分匹配。
  • 样本量与中心数:1216例患者,来自大型学术健康系统内多个ICU(具体中心数原文未提及)。
  • 人群:成人ICU酒精戒断综合征患者,CIWA-Ar≥10,排除术后ICU入住。
  • 干预与对照:苯巴比妥为基础方案 vs 非苯巴比妥为基础方案。
  • 苯巴比妥使用比例:345/1216(28.4%)。
  • 基线特征:苯巴比妥组CIWA-Ar、APACHE III和入ICU前苯二氮䓬暴露更高。
  • 主要终点:校正后苯巴比妥与医院出院时间无显著关联(DRR 0.91;95%CI 0.74-1.12;p=0.370);与ICU出院时间无显著关联(DRR 0.77;95%CI 0.59-1.01;p=0.057)。
  • 安全终点:低血压和插管相似,误吸在苯巴比妥组更少。

证据类型、等级与局限

  • 证据类型:多中心回顾性队列研究。
  • 局限:回顾性设计,可能存在残余混杂;苯巴比妥使用反映治疗升级,提示适应证偏倚;具体中心数、剂量方案及不良事件详细数据原文未提及。

对床旁实践的改变

  • 在ICU酒精戒断综合征患者中,苯巴比妥使用应被视为治疗升级的标志,常见于CIWA-Ar更高、病情更重或已暴露苯二氮䓬的患者。
  • 校正后苯巴比妥未显著改变出院时间,低血压和插管风险相似,误吸更少,但研究设计不能证明因果。
  • 原文未提及具体剂量方案,不能据此形成苯巴比妥用药推荐;最佳时机、剂量和患者选择需未来研究确定。
  • 适用人群为CIWA-Ar≥10的成人ICU酒精戒断综合征患者,术后ICU入住患者不适用。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

IMPORTANCE: Phenobarbital use in ICU alcohol withdrawal syndrome (AWS) may reflect severe or refractory withdrawal and treatment escalation, making multicenter data important to understand its use within ICU practice and its relationship with clinical outcomes.

OBJECTIVES: To evaluate phenobarbital use in real-world ICU AWS as a marker of severe or refractory withdrawal and treatment escalation. We also examined its association with time-to-discharge and safety outcomes compared with nonphenobarbital regimens.

DESIGN, SETTING, AND PARTICIPANTS: Multicenter retrospective cohort study using multiple imputation and propensity score matching. Adults with AWS, defined as Clinical Institute Withdrawal Assessment for Alcohol, revised (CIWA-Ar) score greater than or equal to 10, were included if they received a phenobarbital-based or nonphenobarbital-based regimen in ICUs across a large academic health system from June 30, 2017, to July 1, 2024. Postoperative ICU admissions were excluded.

MAIN OUTCOMES AND MEASURES: Primary outcomes were time to ICU and hospital discharge alive from treatment initiation. Safety outcomes were hypotension, new intubation, and aspiration within 48 hours.

RESULTS: Of 1216 patients, 345 (28.4%) received phenobarbital. Before matching, phenobarbital-treated patients had higher CIWA-Ar, Acute Physiology and Chronic Health Evaluation III, and pre-ICU benzodiazepine exposure, consistent with more severe or refractory withdrawal. In adjusted time-to-discharge models, phenobarbital use was not significantly associated with time to hospital discharge alive (discharge rate ratio [DRR], 0.91; 95% CI, 0.74-1.12; p = 0.370) or ICU discharge alive (DRR, 0.77; 95% CI, 0.59-1.01; p = 0.057). Hypotension and intubation were similar, and aspiration was less frequent with phenobarbital.

CONCLUSIONS: In a contemporary ICU cohort, phenobarbital use reflected treatment escalation in patients with more severe or refractory AWS. After adjustment, time to ICU and hospital discharge alive did not differ significantly, hypotension and intubation were similar, and aspiration was less frequent with phenobarbital. Future studies should define optimal timing, dosing, and patient selection.

来源:Crit Care Explor,查看原文。版权归原作者所有。

参考来源

  1. Rizwan ZM, Heybati K, Dierkhising R, et al. Real-World Phenobarbital Use, Treatment Escalation, and Clinical Outcomes in Critically Ill Patients With Alcohol Withdrawal Syndrome: A Multicenter Propensity-Matched Cohort Study. Crit Care Explor. 2026. PMID: 42611632. doi:10.1097/CCE.0000000000001466

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。